cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Pharvaris Nv
5 own
6 watching
Current Price
$20.35
$-1.36
(-6.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
685.25M
52-Week High
52-Week High
33.00000
52-Week Low
52-Week Low
8.20000
Average Volume
Average Volume
0.03M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization685.25M
icon52-Week High33.00000
icon52-Week Low8.20000
iconAverage Volume0.03M
iconDividend Yield--
iconP/E Ratio--
What does the Pharvaris Nv do?
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More
News & Events about Pharvaris Nv.
TipRanks Financial Blog
10 months ago
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Paycor HCM (PYCR Research Report), Regeneron (RE... Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Paycor HCM (PYCR Research Report), Regeneron...
Globe Newswire
1 year ago
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1 ...
Globe Newswire
1 year ago
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study ...
Zolmax
1 year ago
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have earned an average recommendation of Moderate Buy from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has ...
Ticker Report
1 year ago
Pharvaris (NASDAQ:PHVS Get Rating) had its price objective trimmed by SVB Leerink from $20.00 to $18.00 in a report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, JMP Securities increased their target price on Pharvaris from $22.00...
Frequently Asked Questions
Frequently Asked Questions
What is Pharvaris Nv share price today?
plus_minus_icon
Can Indians buy Pharvaris Nv shares?
plus_minus_icon
How can I buy Pharvaris Nv shares from India?
plus_minus_icon
Can Fractional shares of Pharvaris Nv be purchased?
plus_minus_icon
What are the documents required to start investing in Pharvaris Nv stocks?
plus_minus_icon
What is today’s traded volume of Pharvaris Nv?
plus_minus_icon
What is today’s market capitalisation of Pharvaris Nv?
plus_minus_icon
What is the 52-Week High and Low Range of Pharvaris Nv?
plus_minus_icon
What percentage is Pharvaris Nv down from its 52-Week High?
plus_minus_icon
What percentage is Pharvaris Nv up from its 52-Week Low?
plus_minus_icon
Current Price
$20.35
$-1.36
(-6.26%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00